Drug Discovery World

NOVEMBER 1, 2022

Ground-breaking therapies . The company said: “As of the 28 September 2022, patients have been dosed with Auceliciclib, and dosing has completed for Cohorts 1 – 5 of the monotherapy dose escalation, and Cohorts 1a, 1b for the combination therapy arms with Temozolomide (TMZ).

Drugs 130

Drugs Science Therapies Clinical Trials 130

Drug Discovery World

APRIL 27, 2023

Recently, researchers at the Broad Institute of MIT Harvard, Boston Children’s Hospital, and Dana-Farber Cancer Institute have found that HSC are particularly vulnerable to ferroptosis, a kind of cell death triggered by iron. Previously, scientists have studied ferroptosis mostly in cancer cells.

Small Molecule 130

Small Molecule Science Drugs FDA Approval 130

Drug Discovery World

JUNE 5, 2023

Showcase agenda Throughout the day, there were a number of presentations on the exhibition floor which provided company updates and showcased a number of exciting results and projects, highlighting both how far we have come in the treatment of disease, as well as how far there is still to go.

Small Molecule 130

Small Molecule Treatment Science Disease 130

KIF1A

OCTOBER 3, 2024

Her leadership and vision have resulted in the establishment of crucial research initiatives, including a vision study and a speech study, alongside the development of gene therapy approaches and biomarkers specifically for KAND. We know that living with a rare disease can be an overwhelming and isolating journey.

Small Molecule 52

Small Molecule Research Treatment Therapies 52

PLOS: DNA Science

SEPTEMBER 5, 2024

Gleevec is a small molecule that interferes with entry of an enzyme – a tyrosine kinase – that enables growth signals to enter specific cells and trigger division. A name ending in “nib” means a small molecule that inhibits an enzyme called a kinase, and is short for “inhibit.”

Treatment 52

Treatment FDA Approval DNA Small Molecule 52

The Pharma Data

JANUARY 17, 2021

The primary endpoint of the study was composite of time to first occurrence of heart failure hospitalization or cardiovascular death. The study enrolled 5,050 patients who received either vericiguat or placebo in combination with available heart failure therapies. HFrEF was formerly known as systolic heart failure.

FDA 52

FDA Small Molecule Immune Response Hospitals 52

The Pharma Data

NOVEMBER 18, 2020

In addition, OBI-833 can elicit a beneficial immune response in NSCLC patients and had rendered some TKI-treated patients a durable stable disease status. Title: A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients. Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

Agency IQ

NOVEMBER 3, 2023

regulatory landscape for probiotics and other microbiome-based therapies Probiotics, a type of microbiome-based therapy containing live micro-organisms, are broadly available on drug store and grocery store shelves, but the regulatory classifications for products containing the same micro-organism can differ dramatically.

Therapies 40

Therapies Science FDA Production 40

The Pharma Data

JUNE 17, 2022

Tens of millions of older children across the globe have already been vaccinated with our COVID-19 vaccine, helping to prevent symptomatic, severe disease and hospitalization. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.

Vaccine 52

Vaccine FDA Clinical Trials Immune Response 52

The Pharma Data

APRIL 23, 2021

European Commission approves GSK’s JEMPERLI (dostarlimab), the first anti-PD-1 therapy approved for recurrent or advanced endometrial cancer. The approval makes dostarlimab the first anti-PD-1 therapy available for endometrial cancer in Europe. and a disease control rate of 55.6% (95% CI; 45.7-65.1). Issued: London UK.

Therapies 52

Therapies Treatment Licensing Licensing 52

The Pharma Data

MARCH 24, 2021

Boehringer Ingelheim stepped up its investments in R&D significantly in 2020 in pursuit of innovative medicines and therapies for diseases for which no satisfactory treatments are available. In particular, efforts to research potential COVID-19 related therapies were accelerated. The company spent 3.7 billion EUR.

Vaccine 52

Vaccine Small Molecule Disease Therapies 52

The Pharma Data

DECEMBER 17, 2020

Most recently, Cadavid served as senior vice president and Head of Clinical Development at Fulcrum Therapeutics where he led the development of multiple small molecules for the treatment of genetically defined rare diseases. Thérin is the president of Advanced Therapies at Siemens Healthineers.

Small Molecule 52

Small Molecule Engineering Pharmaceuticals Clinical Development 52

NIH Director's Blog: Drug Development

JULY 20, 2017

Credit: Brittany Mahoney As NIH Director, I often hear stories of how people with serious diseases—from arthritis to Zika infection—are benefitting from the transformational power of NIH’s investments in basic science. Caption: Two-year-old Avalyn is among the cystic fibrosis patients who may be helped by targeted drugs.

Clinical Trials 52

Clinical Trials Small Molecule Disease Therapies 52

The Pharma Data

NOVEMBER 22, 2020

We believe we are well prepared to press forward given our strong balance sheet and pioneering leadership in the development of muscle-directed therapies.”. We look forward to rapidly advancing next steps for omecamtiv mecarbil , which we expect will include discussions with regulatory authorities. Terms of Termination.

Clinical Trials 52

Clinical Trials Licensing Licensing Trials 52

The Pharma Data

JUNE 28, 2021

After seeing a doctor, he was diagnosed with plaque psoriasis—a chronic autoimmune disease that appears on the surface of the skin as raised, red, itchy patches, but actually starts inside the body, caused by dysfunction of the immune system. 1 About 80 percent of the over 8 million people living in the U.S.

Clinical Trials 52

Clinical Trials Treatment Trials Disease 52

The Pharma Data

AUGUST 29, 2020

Oral, investigational complement factor B inhibitor LNP023 substantially improved hematological response as add-on therapy to eculizumab. FDA and EMA have granted orphan drug designations to LNP023 for PNH and the rare renal disease complement 3 glomerulopathy (C3G). Peffault de Latour.

Treatment 52

Treatment Disease Small Molecule Production 52

Drug Discovery World

AUGUST 2, 2023

PPT1 inhibitors for the treatment of patients with cancer Contemplating the potential of PPT1 inhibition in cancer led to the development of small molecules with high PPT1 affinity and limited toxicity for clinical drug development. Therein is an accessible molecular cavity, sufficiently large to accommodate many small molecules 4.

Small Molecule 130

Small Molecule Immune Response Clinical Trials International 130

Drug Discovery World

JANUARY 26, 2023

Research into HIV blossomed throughout 2022, with ViiV Healthcare’s combination therapy for HIV-1 gaining approval in Japan; and research moving forward towards a one-time treatment for HIV as well as a vaccine. In terms of activity, a number of large-scale acquisitions took place, with Pfizer’s purchase of Biohaven for $11.6

Clinical Trials 246

Clinical Trials Drugs Trials Therapies 246

The Pharma Data

NOVEMBER 9, 2020

We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen. Albert Bourla, Pfizer Chairman and CEO. “We About Pfizer: Breakthroughs That Change Patients’ Lives.

Vaccine 40

Vaccine Clinical Trials Trials FDA 40

The Pharma Data

DECEMBER 1, 2020

will reduce the number of people in the high-risk population being hospitalized. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. “The Emergency Use Authorization in the U.K. CEO and Co-founder of BioNTech. “We

Vaccine 40

Vaccine Clinical Trials Trials Production 40

The Pharma Data

OCTOBER 26, 2020

Merck continued to advance the development programs for KEYTRUDA (pembrolizumab), the company’s anti-PD-1 therapy; Lynparza (olaparib), a PARP inhibitor being co-developed and co-commercialized with AstraZeneca; and Lenvima (lenvatinib mesylate), an orally available tyrosine kinase inhibitor being co-developed and co-commercialized with Eisai Co.,

Vaccine 40

Vaccine Trials Licensing Licensing 40

Broad Institute

JUNE 30, 2023

Common genetic variants associated with cardiometabolic disease can produce phenotype changes of such small effect that they can be difficult to characterize. Common genetic variants associated with cardiometabolic disease can produce phenotype changes of such small effect that they can be difficult to characterize.

Small Molecule 105

Small Molecule Cell Based Assays Disease Medical Schools 105

The Pharma Data

AUGUST 3, 2021

BLINCYTO ® (blinatumomab), our BiTE ® immunotherapy, sales increased 16% year-over-year for the second quarter, driven by 18% volume growth as we benefited from broader adoption in the community hospital setting. In the U.S., MVASI continued to hold leading volume share with 50% of the bevacizumab segment in the quarter. Bemarituzumab.

Biosimilars 52

Biosimilars Production Treatment FDA 52

Broad Institute

JUNE 21, 2023

Common genetic variants associated with cardiometabolic disease can produce phenotype changes of such small effect that they can be difficult to characterize. Common genetic variants associated with cardiometabolic disease can produce phenotype changes of such small effect that they can be difficult to characterize.

Small Molecule 52

Small Molecule Cell Based Assays Medical Schools Disease 52

Drug Target Review

MAY 23, 2023

Inflammatory bowel disease (IBD) is an umbrella term that describes complex disorders that cause chronic inflammation in the digestive tract with alternating periods of relapse and remission. Therapies developed in recent decades have transformed the treatment of IBD, making hospitalisation and surgery less common. More than 6.8

Drugs 75

Drugs Small Molecule Production Pharma Companies 75

KIF1A

MAY 31, 2024

Advancing Research at the Chung Lab Recent Move to Boston Children’s Hospital Wendy Chung, MD, PhD, and her team have been our leading partners since the founding of KIF1A.ORG in 2017. In February of 2023, Boston Children’s Hospital named Dr. Chung Chief of the Department of Pediatrics.

Small Molecule 52

Small Molecule Treatment International Research 52

Agency IQ

APRIL 19, 2024

FDA advisors endorse minimal residual disease (MRD) as accelerated approval endpoint for multiple myeloma Last week, FDA’s Oncologic Drugs Advisory Committee (ODAC) voted unanimously in favor of using minimal residual disease (MRD) as an accelerated approval endpoint for multiple myeloma.

FDA 40

FDA Disease Trials Clinical Trials 40

The Pharma Data

AUGUST 3, 2021

The company announced plans to submit donanemab for Alzheimer’s disease and tirzepatide for type 2 diabetes to regulatory authorities by the end of 2021. announced an exclusive collaboration focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immune responses.

Production 52

Production Marketing Research Government 52

The Pharma Data

JANUARY 3, 2021

CAP-1002 is an allogeneic cell therapy in development for Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. XLMTM is a serious, life-threatening neuromuscular disease marked by extreme muscle weakness, respiratory failure, and early death. The DSMB recommended the trial continue as designed.

Small Molecule 52

Small Molecule Trials Vaccine FDA 52

The Pharma Data

DECEMBER 21, 2020

While up to 30% of all patients with NSCLC may be diagnosed early enough to have potentially curative surgery, disease recurrence is still common in early-stage disease and nearly half of patients diagnosed in Stage IB, and over three quarters of patients diagnosed in Stage IIIA, experience recurrence within five years.

Treatment 52

Treatment Trials Disease FDA 52

The Pharma Data

OCTOBER 21, 2020

Importantly, the manufacturing process for our small molecule direct-acting antiviral allows us to produce AT-527 quickly and at scale.”. Atea Pharmaceuticals is a clinical stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases.

RNA 52

RNA Pharmaceuticals Virus Small Molecule 52

The Pharma Data

DECEMBER 20, 2020

ARCA biopharma enrolled the first patients in ASPEN-COVID-10, its Phase IIb trial of rNAPc2 for hospitalized COVID-19 patients. The therapy is a combination of anticoagulant, anti-inflammatory and antiviral effects. Auxora is a potent and selective small molecule CRAC channel inhibitor that prevents CRAC channel overactivation.

Vaccine 52

Vaccine Trials Small Molecule Therapies 52

The Pharma Data

JANUARY 10, 2021

Comparing to Non-Small Cell Lung Cancer(NSCLC), it is still not clear about tumor driving gene in the development of SCLC, and thus it is lacking of targeted therapeutic treatment for this life threaten disease. SH ) was founded in Shenzhen on 2001, specializing in the research and development of novel small molecule drugs.

Clinical Trials 52

Clinical Trials Treatment Trials Small Molecule 52

The Pharma Data

DECEMBER 27, 2020

Vir Biotechnology and GlaxoSmithKline dosed the first patient in a new sub-trial of a Phase III study of monoclonal antibody VIR-7831 for hospitalized adults with COVID-19. The molecule targets two pathways that cause a number of retinal diseases. It reduced the risk of disease progression or death by 78%. Here’s a look.

Clinical Trials 52

Clinical Trials Trials Therapies RNA 52

Codon

JUNE 11, 2024

But these little machines, small enough to fit inside a pocket, have become commonplace. Biologists use nanopores for everything from diagnosing diseases and monitoring changes within rainforest ecosystems to discovering proteins from microbes frozen in Icelandic glaciers. Such a device seems implausible. Cite: Stephen Malina.

DNA 73

DNA Engineering RNA Small Molecule 73

Drug Discovery World

AUGUST 4, 2022

Developability in the biopharmaceutical industry relates to the difficulty of making early candidate molecules with attractive biological activities into commercialised and marketable therapies. Doing this earlier will help minimise costly time delays, or late-stage program failures. Why biopharma struggles with the developability gap.

Drug Development 130

Drug Development Vaccine Production Drugs 130

The Pharma Data

APRIL 7, 2021

Abrocitinib is an oral small molecule that selectively inhibits Janus kinase (JAK) 1. XELJANZ/XELJANZ XR (tofacitinib) is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).

Treatment 52

Treatment Clinical Trials Therapies Vaccine 52